Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

DISEASE CHARACTERISTICS:

* Pathologically proven non-small cell lung cancer (NSCLC)

  * Stage IA-IIIB disease
* Underwent prior complete surgical resection (R0) no more than 2 months ago
* Eligible for cisplatin-based adjuvant chemotherapy

PATIENT CHARACTERISTICS:

* Karnofsky performance status ≥ 70%
* Absolute neutrophil count ≥ 1,500/mm\^3
* Hemoglobin ≥ 8.0 g/dL
* Platelet count ≥ 100,000/mm\^3
* Creatinine clearance \> 55 mL/min
* Total bilirubin normal
* Alkaline phosphatase, AST, and ALT must meet 1 of the following criteria:

  * Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
  * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
  * AP ≤ 5 times ULN AND AST and ALT normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study treatment
* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
* No peripheral neuropathy \> grade 1
* No hearing deficit at baseline, even if it does not require a hearing aid or intervention or interfere with activities of daily life (i.e., CTCAE grade 2 or higher)

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior postoperative radiation therapy
* No prior chemotherapy for NSCLC
* No prior docetaxel or cisplatin
* No concurrent prophylactic filgrastim (G-CSF) or pegfilgrastim